Summit Therapeutics plc Stock
-
Your prediction
Pros and Cons of Summit Therapeutics plc in the next few years
Pros
Cons
Performance of Summit Therapeutics plc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Summit Therapeutics plc | - | - | - | - | - | - | - |
Proteome Sciences | -3.640% | -1.852% | 1.923% | -26.389% | -8.621% | -3.636% | 20.455% |
Oxford BioMedica PLC | 3.470% | 1.456% | 16.111% | 3.980% | -18.039% | -24.685% | -57.416% |
Sareum Holdings plc | - | -5.348% | 19.595% | -55.528% | -41.391% | -92.371% | - |
News

This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
Three years ago, Summit Therapeutics (NASDAQ: SMMT) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time

2 Soaring Stocks With More Upside Potential to Buy and Hold
Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others

Why Summit Therapeutics Stock Soared 8% Higher Today
One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (NASDAQ: SMMT) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped